Key Takeaways CRL's RMS segment grew 6.5% in Q3 2025, led by Noveprim, China, CRADL, GEMS and aca/govt. clients.CRL expands via partnerships with Elly's Team, Parker Institute, CHDI Foundation, Deciphex and Akron Bio.CRL faces cautious biotech spending, NIH-dependent revenues, tariffs and competition across segments.Charles River Laboratories International, Inc.’s (CRL) solid prospects in the Research Models and Services (“RMS”) segment are supported by consistent demand for its research model services. The ...